ubmslateCN-logo-ubm

CN Mobile Logo

Topics:

Oncology and Hematology News and Journal Articles

Recent Content

This slide show highlights some of the top stories of the month, including the approval of a new agent for RCC, a study that found declines in prostate cancer deaths have mirrored the declines in smoking rates, and more.

Afatinib resulted in improved progression-free survival compared with gefitinib in treatment-naive non–small-cell lung cancer patients with EGFR mutations.

A 34-year-old woman presents with abdominal pain, and a duodenal biopsy is obtained. Based on the image shown, what is your diagnosis?

Cancer patients have an increased risk of several common mental disorders, including depression and anxiety, beginning almost a year prior to the diagnosis.

First-line osimertinib, a targeted therapy against EGFR mutations, was found to be effective in patients with advanced non–small-cell lung cancer, resulting in a 77% overall response rate.

Adding ixazomib to the combination of lenalidomide/dexamethasone resulted in a more than 35% improvement in the risk for disease progression or death in patients with relapsed or refractory multiple myeloma.

As part of our coverage of ONS, we discuss dermatologic issues in oncology patients, including skin-related toxicities and assessment techniques used to identify skin-related issues.

By clicking Accept, you agree to become a member of the UBM Medica Community.